These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26100694)

  • 1. A novel point mutation promotes growth phase-dependent daptomycin tolerance in Staphylococcus aureus.
    Mechler L; Herbig A; Paprotka K; Fraunholz M; Nieselt K; Bertram R
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5366-76. PubMed ID: 26100694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin Tolerance in the Staphylococcus aureus pitA6 Mutant Is Due to Upregulation of the dlt Operon.
    Mechler L; Bonetti EJ; Reichert S; Flötenmeyer M; Schrenzel J; Bertram R; François P; Götz F
    Antimicrob Agents Chemother; 2016 May; 60(5):2684-91. PubMed ID: 26883712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and transcriptional activities of Staphylococcus aureus challenged with high-doses of daptomycin.
    Lechner S; Prax M; Lange B; Huber C; Eisenreich W; Herbig A; Nieselt K; Bertram R
    Int J Med Microbiol; 2014 Nov; 304(8):931-40. PubMed ID: 24980509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype.
    Gaupp R; Lei S; Reed JM; Peisker H; Boyle-Vavra S; Bayer AS; Bischoff M; Herrmann M; Daum RS; Powers R; Somerville GA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4226-38. PubMed ID: 25963986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mutation in the vraS gene of Staphylococcus aureus contributes to reduce susceptibility against daptomycin.
    Su J; Iehara M; Yasukawa J; Matsumoto Y; Hamamoto H; Sekimizu K
    J Antibiot (Tokyo); 2015 Oct; 68(10):646-8. PubMed ID: 25899124
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
    Julian K; Kosowska-Shick K; Whitener C; Roos M; Labischinski H; Rubio A; Parent L; Ednie L; Koeth L; Bogdanovich T; Appelbaum PC
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3445-8. PubMed ID: 17620372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Insight into Daptomycin Bioavailability and Localization in Staphylococcus aureus Biofilms by Dynamic Fluorescence Imaging.
    Boudjemaa R; Briandet R; Revest M; Jacqueline C; Caillon J; Fontaine-Aupart MP; Steenkeste K
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4983-90. PubMed ID: 27297479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
    J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus.
    Patel D; Husain M; Vidaillac C; Steed ME; Rybak MJ; Seo SM; Kaatz GW
    Int J Antimicrob Agents; 2011 Nov; 38(5):442-6. PubMed ID: 21840181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between population dynamics and drug tolerance of Staphylococcus aureus persister cells.
    Lechner S; Patra P; Klumpp S; Bertram R
    J Mol Microbiol Biotechnol; 2012; 22(6):381-91. PubMed ID: 23363876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype.
    Begic D; von Eiff C; Tsuji BT
    J Antimicrob Chemother; 2009 May; 63(5):977-81. PubMed ID: 19304733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
    Pillai SK; Gold HS; Sakoulas G; Wennersten C; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2223-5. PubMed ID: 17404001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB; Saravolatz LD; Husain N
    Int J Antimicrob Agents; 2010 Nov; 36(5):478-80. PubMed ID: 20846830
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin non-susceptible Staphylococcus aureus at a US medical centre.
    Velazquez A; DeRyke CA; Goering R; Hoover V; Wallace MR
    Clin Microbiol Infect; 2013 Dec; 19(12):1169-72. PubMed ID: 23480569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
    Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
    J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin.
    Entenza JM; Giddey M; Vouillamoz J; Moreillon P
    Int J Antimicrob Agents; 2010 May; 35(5):451-6. PubMed ID: 20185277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of daptomycin resistance on Staphylococcus aureus virulence.
    Cameron DR; Mortin LI; Rubio A; Mylonakis E; Moellering RC; Eliopoulos GM; Peleg AY
    Virulence; 2015; 6(2):127-31. PubMed ID: 25830650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
    Mariani PG; Sader HS; Jones RN
    J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.